Highlights of the San Antonio Breast Cancer Symposium 2020: part 2

John R Benson; Dorin Dumitru; Ismail Jatoi

doi:10.2217/fon-2021-0333

Highlights of the San Antonio Breast Cancer Symposium 2020: part 2

Future Oncol. 2021 Jul;17(21):2699-2703. doi: 10.2217/fon-2021-0333. Epub 2021 Jun 1.

Authors

John R Benson^{1

2}, Dorin Dumitru^{3

4}, Ismail Jatoi⁵

Affiliations

¹ Cambridge Breast Unit, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK.
² School of Medicine, Anglia Ruskin University, Alan Cherry Dr, Chelmsford, CM1 1SQ, UK.
³ Breast Unit, Hull University Teaching Hospitals NHS Trust, Castle Road, Cottingham, HU16 5JQ, UK.
⁴ Hull York Medical School, Allam Medical Building, University of Hull, Hull, HU6 7RX, UK.
⁵ Division of Surgical Oncology, Dale H Dorn Chair in Surgery, University of Texas Health Science Centre, San Antonio, TX 78299, USA.

PMID: 34058844
DOI: 10.2217/fon-2021-0333

No abstract available

Keywords: CDK 4/6 inhibitors; HER2 positive; Immunotherapy; San Antonio; drug conjugates; metastatic; multigene assays; triple-negative breast cancer.

MeSH terms

Breast Neoplasms / drug therapy*
Breast Neoplasms / metabolism
Breast Neoplasms / pathology
Female
Humans
Immune Checkpoint Inhibitors / therapeutic use*
Prognosis
Protein Kinase Inhibitors / therapeutic use*
Societies, Scientific

Substances

Immune Checkpoint Inhibitors
Protein Kinase Inhibitors